Navigation Links
Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
Date:12/4/2008

DURHAM, N.C., Dec. 4 /PRNewswire/ -- Parion Sciences, Inc. today announced that its partner, Gilead Sciences (Nasdaq: GILD), has initiated a Phase I clinical trial of GS9411 in healthy volunteers to evaluate the safety and tolerability of the investigational compound. GS9411 is designed to increase airway hydration for the treatment of pulmonary disease. Previously known as P-680, GS9411 is an epithelial sodium channel (ENaC) blocker discovered by Parion, a privately held pharmaceutical company focused on treating diseases that result from the failure of the body's mucosal defenses.

The initiation of the Phase I trial triggers a $5 million milestone payment to Parion, according to an exclusive licensing and co-development agreement signed in August 2007 granting Gilead worldwide commercialization rights to GS9411 for the treatment of pulmonary diseases, including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and non-CF bronchiectasis. Parion and Gilead jointly performed the IND-enabling studies for GS9411, and Gilead will assume primary development responsibilities going forward. The two companies are also collaborating on a research program to identify other promising ENaC blocker-based drug candidates utilizing Parion's proprietary ENaC-based chemistry platform.

"This is an important milestone in our program to develop ENaC inhibitors to treat a range of diseases through restoring and maintaining the hydration of mucosal surfaces," said Paul Boucher, Sr. Director, Finance and Business at Parion. "Our partnership with Gilead has enabled us to accelerate development of GS9411 and successfully meet the goals and timelines for this project. We look forward to discovering the potential of this compound to provide a new treatment option for patients suffering from cystic fibrosis, COPD and other s
'/>"/>

SOURCE Parion Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment
2. CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East
3. Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia
4. DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product
5. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
6. Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award
7. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
9. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
10. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
11. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... a world-leading provider of scientific, technical and medical information ... recent study in Reproductive BioMedicine Online ... with an abnormal chromosomal composition can be identified by ... thereby classifying the risk of genetic abnormality without a ... undertaken a retrospective study, using their predictive model to ...
(Date:5/17/2013)... TRIANGLE PARK, N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability , ... and insect pressures , Syngenta ... opening celebration today at the company’s RTP Innovation Center. ... Lab allows company researchers to simulate any agricultural climate ...
(Date:5/17/2013)... May 17, 2013  Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce ... Switzerland -based Kenta Biotech to acquire ... (mAb) products, and technologies. This asset portfolio purchase ... of infections by common pathogens including drug resistant ... Pseudomonas aeruginosa , Acinetobacter baumannii and ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... effectDENVER, March 18 Corgenix Medical Corporation (OTC ... of diagnostic test kits, has announced it will ... 31 at the American College of Cardiology (ACC) ... take place in Orlando, Fla., at the Orange ...
... Despite the initial regulatory hiccups, the number of ... increase gradually. The patent expiry of key biopharmaceuticals ... driving the development of biosimilars. In addition, payers, ... drugs due to their safety, efficacy and affordability, ...
... March 18 , ... Education,Communication and Compliance Challenges of Radiologic Technologists, Managers ... introduced Mosby,s Imaging Suite,( http://www.mosbysimagingsuite.com ), the first ... research, education, communication and,compliance challenges of radiologic technologists ...
Cached Biology Technology:Corgenix to Exhibit AspirinWorks(R) Test at ACC.09 2Corgenix to Exhibit AspirinWorks(R) Test at ACC.09 3The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 2The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 3The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan 4New Online Imaging Suite Boosts Healthcare Imaging Efficiency, Productivity, and Revenues 2New Online Imaging Suite Boosts Healthcare Imaging Efficiency, Productivity, and Revenues 3New Online Imaging Suite Boosts Healthcare Imaging Efficiency, Productivity, and Revenues 4
(Date:5/17/2013)... Bethesda, MD (May 18, 2013) The AGA Research ... research into the relationship between the gut microbiota, one ... health and disease. , The AGA Research Awards ... colleagues from Massachusetts General Hospital and Harvard Medical School, ... Award recipient. Dr. Chan will receive $25,000 of funding, ...
(Date:5/17/2013)... Shenzhen, China---- Why Tibetan antelope can live at ... a collaborative research published in Nature Communications ... institutes provide evidence that some genetic factors may ... highland environments. The data in this work will ... and the biology of other ruminant species. , ...
(Date:5/16/2013)... 17, 2013) Illustrating a commitment to the ... Gastroenterological Association (AGA) Research Foundation has announced the ... Fellowship Award recipients. Supported by the National Institute ... this new award helps underrepresented minority students to ... nutrition research. , "By establishing this new award, ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
... two most important recreational fisheries off Southern California ... by a researcher from Scripps Institution of Oceanography ... Brad Erisman and his colleagues examined the health ... kelp bass-staple catches of Southern California,s recreational fishing ...
... Steve Bergens and his graduate student Jeremy Johns ... to revolutionise the chemical industry by reducing its ... Their findings were published in a top international ... the chemical industry with a potential solution to ...
... -- The National Institutes of Health (NIH) has awarded a ... research into risk factors for spina bifida and related congenital ... or brain is not fully enclosed. The research will ... E. Mason at Weill Cornell Medical College. Dr. Ross is ...
Cached Biology News:'Illusion of plenty' masking collapse of 2 key Southern California fisheries 2Catalyst discovery has potential to revolutionize chemical industry 2NIH awards $5.5 million grant to Weill Cornell for research into preventing spina bifida 2NIH awards $5.5 million grant to Weill Cornell for research into preventing spina bifida 3
sodium channel, nonvoltage-gated 1 alpha,...
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SGG (Sheep gamma globulin) lysine through amide bonds. This product is homologous to NP-BSA....
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
... ideal for use in refrigerators, freezers, or liquid nitrogen. ... colors allow for color coding to project, user, lab, ... or promote cool air circulation. Supplied with 9 x ... Box dimensions: 13 x 13 x 5.1 ...
Biology Products: